CDC. 2002j. Section 13a: study summary: enhanced signal detection and hypothesis testing for adverse events following anthrax vaccination. Anthrax Vaccine Safety and Efficacy Plan. Atlanta: Centers for Disease Control and Prevention.
CDC. 2002k. Section 13b: the memorandum of understanding (MOU) between AVSA/NIP/CDC and AMSA/USACHPPM/DoD. Anthrax Vaccine Safety and Efficacy Plan. Atlanta: Centers for Disease Control and Prevention.
CDC. 2002l. Section 14: study summary: possible role of aluminum hydroxide adjuvant in AVA-associated adverse events, potential areas for future research. Anthrax Vaccine Safety and Efficacy Plan. Atlanta: Centers for Disease Control and Prevention.
DoD (Department of Defense). 2002. News release: agreement on federal health information exchange announced. Department of Defense, Washington, D.C.
Eickhoff TC, Myers M. 2002. Workshop summary: aluminum in vaccines. Vaccine 20:S1–S4.
Gherardi RK, Coquet M, Cherin P, Authier FJ, Laforet P, Belec L, Figarella-Branger D, Mussini JM, Pellissier JF, Fardeau M. 1998. Macrophagic myofasciitis: an emerging entity. Groupe d’Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l’Association Francaise contre les Myopathies (AFM). Lancet 352(9125):347–352.
Gherardi RK, Coquet M, Cherin P, Belec L, Moretto P, Dreyfus PA, Pellissier JF, Chariot P, Authier FJ. 2001. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 124:1821–1831.
Grabenstein JD. 2001. VAERS information; average length of active duty. E-mail to Joellenbeck L, Institute of Medicine , Washington, D.C., November 13.
IOM (Institute of Medicine). 2001. CDC Anthrax Vaccine Safety and Efficacy Research Program. Interim Report. Washington, D.C.: National Academy Press.
IOM. 2002. Joellenbeck LM, Zwanziger LL, Durch JS, Strom BL, eds. The Anthrax Vaccine: Is It Safe? Does It Work? Washington, D.C.: National Academy Press.
MacKay L, Chu DS. 2002. Memorandum of agreement for federal health information exchange governance and management. Department of Veterans Affairs and Department of Defense, Washington, D.C.
Niu MT, Erwin DE, Braun MM. 2001. Data mining in the U.S. Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination. Vaccine 19(32):4627– 4634.
VAERS (Vaccine Adverse Event Reporting System). 2001. A federal program for surveillance of vaccine safety. Brochure. Rockville, Md.: Vaccine Adverse Events Reporting System.
Ware JE, Snow KK, Kosinski M, Gandek B. 1993. SF-36 Health Survey Manual and Interpretation Guide. Boston: New England Medical Center, The Health Institute.
Wolfowitz P. 2002. Reintroduction of the Anthrax Vaccine Immunization Program (AVIP). Memorandum for Secretaries of the Military Departments; Chairman of the Joint Chiefs of Staff; Undersecretaries of Defense; Assistant Secretaries of Defense; General Counsel, Department of Defense; Inspector General, Department of Defense; Directors of Defense Agencies; Commandant of the U.S. Coast Guard. Department of Defense, Washington, D.C.